1The risk of prostate cancer for men on aspirin, statin or antidiabetic medicationsEuropean Journal of Cancer  Clinical Article
2Image guided focal therapy of MRI-visible prostate cancer: Defining a 3D treatment margin based on MRI-histology co-registration analysisThe Journal of Urology  Clinical Article
3A randomised phase II trial comparing docetaxel plus prednisone with docetaxel plus prednisone plus low-dose cyclophosphamide in castration-resistant prostate cancerChemotherapy  Clinical Article
4Population-based analysis of salvage radical prostatectomy with examination of factors associated with adverse perioperative outcomesUrologic Oncology: Seminars and Original Investigations  Clinical Article
5Testosterone replacement therapy in hypogonadal men following prostate cancer treatment: A questionnaire-based retrospective study among urologists in Bavaria, GermanyUrologia Internationalis  Clinical Article
6Aldehyde dehydrogenase is regulated by Beta-catenin/TCF and promotes radioresistance in prostate cancer progenitor cellsCancer Research  Clinical Article
7Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experienceOncogene  Review Article
8Outcomes of radical cystectomy in potential candidates for bladder preservation therapyUrology  Clinical Article
9Comparison between extracorporeal shock wave lithotripsy and ureteroscopic lithotripsy for treating large proximal ureteral stones: A meta-analysisUrology  Clinical Article
10Intra-arterial chemotherapy for muscle-invasive bladder cancer following transurethral resectionUrologia Internationalis  Clinical Article
1FDA approves new antibacterial drug AvycazFDA Press Announcements
2Early evidence of increase in higher-risk prostate cancers from 2011-2013American Society of Clinical Oncology (ASCO) News
3Men who have had testicular cancer are more likely to develop prostate cancer, although overall risk of developing aggressive disease is lowAmerican Society of Clinical Oncology (ASCO) News
4Active surveillance of intermediate-risk prostate cancer associated with decreased survivalAmerican Society of Clinical Oncology (ASCO) News
5New health care delivery model for prostate cancer care results in improved quality, better outcomes for patientsKaiser Permanente Health Research News
6Androgen receptor abnormality may not be associated with primary resistance to taxane chemotherapyAmerican Society of Clinical Oncology (ASCO) News
7New target for prostate cancer treatment discovered by Keck Medicine of USC researchersKeck School of Medicine of USC - Research News
8New target for prostate cancer treatment foundUniversity of Southern California Health News
9New implant for treating enlarged prostate offered by Beaumont urologistBeaumont Health System
10BWH study provides evidence for new approaches to prostate cancerBrigham and Women's Hospital

Show Me:

Chromogranin A staining as a biomarker for prostate adenocarcinoma

As reported in The Prostate, chromogranin A (CgA) staining, an indicator of neuroendocrine differentiation, is associated with decreased biochemical control, clinical failure, increased distant metastases, and decreased cause-specific survival in patients with prostate adenocarcinoma and a GS ≥ 7 (n=285). The median follow-up was 6.5 y. CgA staining was present in 31% of specimens. The 10-y distant metastases rate in specimens with <1% and >1% CgA staining was 8% and 48%, respectively. The 10-y cause-specific survival in specimens with <1% and >1% CgA staining was 95% vs. 76%, respectively.

Water restriction improves nocturia

As reported in the International Journal of Urology, daytime/night-time water restriction significantly improves nocturia in patients with urine production ≥ 30 mL/kg.

NSAID use inversely related to prostate cancer incidence and mortality

Based on a meta-analysis reported in BMC Medicine, NSAID use is associated with a decreased risk of prostate cancer (OR=0.92 [total] and 0.81 [advanced]) and prostate cancer-specific mortality (HR=0.86 [total] and 0.81 [advanced]).

Are YOU the Smartest Doc in America?

The Smartest Doc from MDLinx keeps you current with a competitive edge, pitting colleagues against one other for the title of The Smartest Doc in America.

Take the Challenge

Clinical Pearls

Clinical Pearl from Smartest DocMMP-3 genotypes are associated with congenital anomalies of the kidney and urinary tract and obstructive uropathies in pediatric patients.

Clinical Pearl from Smartest DocChildren and adolescents with an abnormal renal ultrasonographic finding are at high risk for the development of renal scarring.

Clinical Pearl from Smartest DocUreteral stenosis is the most common urological complication after kidney transplantation.

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List